Its no wonder that, since this new class of appetite-curbing GLP-1 medications, including Ozempic, Wegovy, and Zepbound, burst into public consciousness, nearly $1 billion of venture capital dollars have been injected into the growing sector of weight-loss companies, which is now awash with startups prescribing the drugs, according to PitchBook data from the last year and a half
Proofreading for 100% accuracy and persuasion You expect perfection we deliver nothing less
A probiotic that supports microbial balance and gut barrier function may reduce fermentation-driven gas
Sadly, most people arent getting that guidance from an MD or RD, says Grunvald
By helping regulate blood sugar and reduce appetite, these drugs have made sustainable weight loss a reality for many
More questions than answers